AU785365B2 - Butylnitrone containing compositons for inhibition of cancer development - Google Patents

Butylnitrone containing compositons for inhibition of cancer development Download PDF

Info

Publication number
AU785365B2
AU785365B2 AU47915/01A AU4791501A AU785365B2 AU 785365 B2 AU785365 B2 AU 785365B2 AU 47915/01 A AU47915/01 A AU 47915/01A AU 4791501 A AU4791501 A AU 4791501A AU 785365 B2 AU785365 B2 AU 785365B2
Authority
AU
Australia
Prior art keywords
pbn
tert
butylnitrone
diet
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU47915/01A
Other languages
English (en)
Other versions
AU4791501A (en
Inventor
Robert A Floyd
Kenneth Hensley
Yashige Kotake
Dai Nakae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of AU4791501A publication Critical patent/AU4791501A/en
Application granted granted Critical
Publication of AU785365B2 publication Critical patent/AU785365B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU47915/01A 2000-03-30 2001-03-28 Butylnitrone containing compositons for inhibition of cancer development Ceased AU785365B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19357200P 2000-03-30 2000-03-30
US60/193572 2000-03-30
PCT/US2001/010508 WO2001074349A1 (en) 2000-03-30 2001-03-28 Butylnitrone containing compositons for inhibition of cancer development

Publications (2)

Publication Number Publication Date
AU4791501A AU4791501A (en) 2001-10-15
AU785365B2 true AU785365B2 (en) 2007-02-08

Family

ID=22714183

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47915/01A Ceased AU785365B2 (en) 2000-03-30 2001-03-28 Butylnitrone containing compositons for inhibition of cancer development

Country Status (6)

Country Link
US (1) US6569902B2 (enExample)
EP (1) EP1267860A1 (enExample)
JP (1) JP2004500411A (enExample)
AU (1) AU785365B2 (enExample)
CA (1) CA2404291A1 (enExample)
WO (1) WO2001074349A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
EP1922075A4 (en) * 2005-08-04 2009-10-14 Oklahoma Med Res Found ADJUVANT CHEMOTHERAPY FOR ANAPLASTIC GLIOMAS
JP5236641B2 (ja) * 2006-07-25 2013-07-17 ハフ イヤ インスティテュート 急性音響外傷の治療方法
CA2735859C (en) 2008-09-02 2016-08-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl tert-butyl nitrone for the treatment of gliomas
CN110373380B (zh) * 2019-06-14 2022-01-28 中国科学院生态环境研究中心 一种肝脏类器官模型及其建立方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2044829T3 (es) * 1989-10-17 1995-01-16 Oklahoma Med Res Found Metodo y composiciones para la inhibicion de alteraciones asociadas con las lesiones oxidativas de los tejidos.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH 47(24 PART I) (1987) PP 6731-6740 *
CANCER RESEARCH 58(20) (1998) PP 4548-4551 *
J NARA MEDICAL ASSOC 51(6)(2000) PP 468-482 *

Also Published As

Publication number Publication date
US20020004531A1 (en) 2002-01-10
US6569902B2 (en) 2003-05-27
CA2404291A1 (en) 2001-10-11
JP2004500411A (ja) 2004-01-08
WO2001074349A1 (en) 2001-10-11
EP1267860A1 (en) 2003-01-02
AU4791501A (en) 2001-10-15

Similar Documents

Publication Publication Date Title
Lee et al. Flavivirus activates phosphatidylinositol 3-kinase signaling to block caspase-dependent apoptotic cell death at the early stage of virus infection
Kang et al. α‐Synuclein stimulation of monoamine oxidase‐B and legumain protease mediates the pathology of Parkinson's disease
Williams et al. Large hepatitis delta antigen activates STAT‐3 and NF‐κB via oxidative stress
Song et al. Exercise training attenuates age-induced changes in apoptotic signaling in rat skeletal muscle
Stack et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease
Silva et al. CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism
Gardian et al. Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity
Fang et al. Astilbin protects from sepsis‐induced cardiac injury through the NRF2/HO‐1 and TLR4/NF‐κB pathway
Li et al. Cytochrome P450 2J2 is protective against global cerebral ischemia in transgenic mice
Taleb et al. Hsp70 inhibits aminoglycoside-induced hair cell death and is necessary for the protective effect of heat shock
Gao et al. Inhibitory effect of picroside II on hepatocyte apoptosis 1
Lee et al. The role of STAT1/IRF-1 on synergistic ROS production and loss of mitochondrial transmembrane potential during hepatic cell death induced by LPS/d-GalN
Han et al. Neuronal SH2B1 attenuates apoptosis in an MPTP mouse model of Parkinson's disease via promoting PLIN4 degradation
US6569902B2 (en) Nitrone inhibition of cancer development
Conti et al. Inducible nitric oxide synthase (iNOS) in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system
Abhilash et al. Aging and MPTP sensitivity depend on molecular and ultrastructural signatures of astroglia and microglia in mice substantia nigra
US5888982A (en) Regulation of vascular smooth muscle cell heme oxygenase-1
Barraud et al. Enhanced duck hepatitis B virus gene expression following aflatoxin B exposure
Peng et al. Caspase inhibition by cardiotrophin‐1 prevents neuronal death in vivo and in vitro
CN106038695B (zh) 鳄梨萃取物、鳄梨醇b及(2r,4r)-1,2,4-三羟基十七碳-16-炔的用途，以及包含鳄梨萃取物的保健食品
Fan et al. Enhanced inducible nitric oxide synthase expression and nitrotyrosine accumulation in experimental granulomatous hepatitis caused by Toxocara canis in mice
US20200362030A1 (en) Caveolin-1 antibody for use in treating brain inflammation and injury and improving functional recovery
Lee et al. Role of nitric oxide in the pathogenesis of encephalomyocarditis virus-induced diabetes in mice
Anderson et al. Theiler’s murine encephalomyelitis virus induces rapid necrosis and delayed apoptosis in myelinated mouse cerebellar explant cultures
Zhou et al. Ephedrine Attenuates LPS‐Induced Acute Lung Injury in Mice by Inhibiting OTUB1 and Promoting K48 Ubiquitination of HIF1α